Recommended Topic Related To:


"The U.S. Food and Drug Administration today approved Liposorber LA-15 System to treat pediatric patients with primary focal segmental glomerulosclerosis (FSGS) either before transplant, or after renal (kidney) transplantation in which there is re"...



FOSRENOL is a phosphate binder indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).

Management of elevated serum phosphorus levels in end stage renal disease patients usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis and reduction of intestinal phosphate absorption with phosphate binders.


Divide the total daily dose of FOSRENOL and take with or immediately after meals. The recommended initial total daily dose of FOSRENOL is 1500 mg. Titrate the dose every 2-3 weeks until an acceptable serum phosphate level is reached. Monitor serum phosphate levels as needed during dose titration and on a regular basis thereafter.

In clinical studies of ESRD patients, FOSRENOL doses up to 4500 mg were evaluated. Most patients required a total daily dose between 1500 mg and 3000 mg to reduce plasma phosphate levels to less than 6.0 mg/dL. Doses were generally titrated in increments of 750 mg/day.

Chew or crush tablets completely before swallowing. Do not swallow intact tablets.

Consider crushing tablets completely for patients with poor dentition.

Consider potential drug interactions when prescribing FOSRENOL [see DRUG INTERACTIONS].


Dosage Forms And Strengths

Chewable Tablets: 500 mg, 750 mg, and 1000 mg.

Storage And Handling

FOSRENOL is supplied as a chewable tablet in three dosage strengths for oral administration: 500 mg tablets, 750 mg tablets, and 1000 mg tablets. Each chewable tablet is white to off-white round, flat with a bevelled edge, and debossed on one side with 'S405' and the dosage strength corresponding to the content of elemental lanthanum.

500 mg Patient Pack (2 bottles of 45 tablets, NDC 54092-252-45, per each patient pack) NDC 54092-252-90.

750 mg Patient Pack (6 bottles of 15 tablets, NDC 54092-253-15, per each patient pack) NDC 54092-253-90.

1000 mg Patient Pack (9 bottles of 10 tablets, NDC 54092-254-10, per each patient pack) NDC 54092-254-90.


Store at 25°C (77°F): excursions permitted to 15-30°C (59-86°F). [See USP controlled room temperature].

Protect from moisture.

Manufactured by DSM Pharmaceuticals Inc., 5900 NW Greenville Blvd, Greenville, NC 27834. Manufactured for Shire US Inc., Wayne, PA 19087. Revised: 10/2012

Last reviewed on RxList: 11/14/2012
This monograph has been modified to include the generic and brand name in many instances.


Fosrenol - User Reviews

Fosrenol User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Fosrenol sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.